Traded Jul 1, 2025 · largest single transaction ~$259
Show all 3 transactions
Jul 1, 2025~$257 · 250 sh @ $1.03
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
JUNS · NASDAQ · Pharmaceutical Preparations
Jupiter Neurosciences (JUNS) · oqro.io/stocks/JUNS · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
No open-market purchase by an insider of Jupiter Neurosciences was filed in the last 90 days. The latest on record was on Jul 4, 2025.
Since 2025, Jupiter Neurosciences insiders reported 21 open-market purchases and 0 sales on Forms 4 and 5, with purchases in 1 different year, most recently 2025.
No open-market sale by an insider of Jupiter Neurosciences (JUNS) was filed with the SEC in the last 90 days.
No trade in Jupiter Neurosciences (JUNS) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
$1.46−0.06 (−3.95%)
Close of Nov 19, 2026, vs Nov 18 · end-of-day
−98.5% (−$96.04) from Nov 19, 2025 to Nov 19, 2026 · adjusted daily closes
No disclosed open-market insider trades, politician trades or fund 13F changes in this period.
Adjusted close went from $97.50 on Nov 19, 2025 to $1.46 on Nov 19, 2026 (−98.5%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in Jupiter, Fl.
Last 12 months
−98.5%
Market value
$1.31M
S&P 500 +8.0% over the same dates. Prices adjusted for splits and dividends.
Short interest: 25K shares sold short (2.8% of shares outstanding), −34.9% vs the previous count, 1.4 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Revenue
$24K
Free cash flow, last 12 months
—
Cash from operations minus capital spending
Net debt
—
Net income, last 12 months
−$9.2M
Operating profit covers interest -36x
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO.
Revenue, fiscal 2025
$22K
Year ended Dec 31, 2025
Net income, fiscal 2025
−$8.64M
A loss for the year
Shares outstanding
770K
As of Aug 14, 2026
Traded Jul 1, 2025 · largest single transaction ~$259
Jul 1, 2025~$257 · 250 sh @ $1.03
Jul 1, 2025~$257 · 250 sh @ $1.03
DetailsOfficial recordJul 1, 2025~$259 · 250 sh @ $1.03
DetailsOfficial recordTraded Jul 1, 2025 · largest single transaction ~$3.2K
Jul 1, 2025~$505 · 500 sh @ $1.01
DetailsOfficial recordJul 1, 2025~$3.2K · 3,100 sh @ $1.02
DetailsOfficial recordPrices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Notice of delisting or failure to meet listing rules
8-K on sec.govSaid its annual or quarterly report would be late
NT 10-K on sec.govNotice of delisting or failure to meet listing rules
8-K on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
Insiders of Jupiter Neurosciences reported 21 open-market purchases and 0 sales since 2025; purchases in 2025.
| Year | Bought | Sold |
|---|---|---|
| 2025 | $14K21×21 trades | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 8,000 words.
Jupiter Neurosciences, Inc. is a clinical stage research and development pharmaceutical company located in Jupiter, Florida. The Company is advancing a therapeutic pipeline targeting CNS disorders and rare diseases, while also expanding into the consumer longevity market with its Nugevia product line. Both efforts are powered by JOTROL™, Jupiter’s proprietary, enhanced resveratrol formulation that has demonstrated potential for improved bioavailability compared to standard resveratrol. The Company’s therapeutic development pipeline is focused broadly on CNS disorders, presently with a planned Phase IIa clinical study in Parkinson’s disease.
And 18 more headings in the filing.
Source: SEC EDGAR, Form 10-K filed Apr 1, 2026. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Latest annual report filed Apr 1, 2026, compared with the one filed Mar 28, 2025. Read the filing
And 13 more headings in the filing.
From time to time, we are involved in various legal proceedings arising from the normal course of business activities. We are not presently a party to any litigation the outcome of which, we believe, if determined adversely to us, would individually or taken together have a material adverse effect on our business, operating results, cash flows or financial condition. Defending such proceedings is costly and can impose a significant burden on management and employees.
Source: SEC EDGAR, Form 10-K filed Apr 1, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
Off-exchange trading: 63.8% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (4.2% on ATS, 59.6% with other brokers), above its 10-week average of 54.4%. Weeks of Sep 21 to Oct 16, 2026.
Largest ATS: IBKR ATS (19.1%), UBS ATS (15.4%), INTELLIGENT CROSS LLC (14.0%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
Contracts, lobbying and filings
Company reports, price and press
Things to keep in mind
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Against the S&P 500 over the year
Since Nov 17, 2025, JUNS is down 98.5% and the index fund is up 7.5%: 106 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much JUNS moves
Beta 1.6 (1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 249 trading days (1 = in step with it).